Indivior logo

INDV - Indivior News Story

148.1p 0.1  0.1%

Last Trade - 14/05/21

Market Cap £1.09bn
Enterprise Value £617.6m
Revenue £478.1m
Position in Universe 413th / 1826

Indivior PLC - Notice of Results

Wed 11th April, 2018 7:01am
RNS Number : 4741K
Indivior PLC
11 April 2018


Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call


Slough, UK, and Richmond, VA, 11 April 2018 - Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2nd at 12:00 p.m. London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at


Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on May 2nd.


Access the Live Webcast for the Results Call on May 2nd

The webcast event will be available on the "Investors" section of the company's website at The webcast link is Participants also may access the results presentation telephonically: US participants 1-323-794-2149; international participants 44(0)330-336-9411. Please reference confirmation number 1140953. A replay of the presentation will be available at


About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more.



Jason Thompson

Vice President, Investor Relations

Tel: 804-423-8916 or

This information is provided by RNS
The company news service from the London Stock Exchange
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.